Novartis's everolimus gains first European approval for rare benign brain tumour
This article was originally published in Scrip
Executive Summary
Swissmedic, the Swiss Agency for Therapeutic Products, has granted Novartis' everolimus its first European approval for the treatment of a benign brain tumour associated with tuberous sclerosis (TS), a rare genetic disease. The approval is for the use of everolimus in patients aged three years and older with subependymal giant cell astrocytoma (SEGA) associated with TS, for whom surgery is not a suitable option. It will be sold under the trade name Votubia.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.